Acadian Asset Management
NMRA icon

Acadian Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Acadian Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$907K Buy
536,186
+154,692
+41% +$295K ﹤0.01% 1293
2026
Q1 		$738K Buy
381,494
+142,185
+59% +$368K ﹤0.01% 1255
2025
Q4 		$426K Sell
239,309
-33,173
-12% -$72.6K ﹤0.01% 1349
2025
Q3 		$491K Sell
272,482
-395,603
-59% -$639K ﹤0.01% 1222
2025
Q2 		$487K Buy
668,085
+648,411
+3,296% +$491K ﹤0.01% 1144
2025
Q1 		$19K Buy
+19,674
New +$33.7K ﹤0.01% 1535
2024
Q4 		– Sell
-4,439
Closed -$58K – 1992
2024
Q3 		$58K Buy
+4,439
New +$51.8K ﹤0.01% 1757

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management's NMRA Position: Q2 2026 in Review

Acadian Asset Management increased its Neumora Therapeutics (NMRA) stake by 41% in Q2 2026, buying an estimated $295K and bringing the position to 536,186 shares worth $907K. The position accounts for ﹤0.01% of the portfolio, ranked #1293.

Acadian Asset Management first reported a position in NMRA in Q3 2024 and has held it in 7 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Acadian Asset Management held 536,186 shares of Neumora Therapeutics worth $907K as of Q2 2026.
  • Acadian Asset Management bought 154,692 Neumora Therapeutics shares in Q2 2026, an estimated $295K.
  • Neumora Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1293 holding.
  • Acadian Asset Management first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.